Novera is a life science company, pioneering the direct delivery of energy (ATP) to cells for wound healing applications. Overa plans to align itself with relevant experts to quicken the development process and improve its chances of success, structuring these relationships such that they greatly reduce the operating cost associated with new drug development. Continuing with its commitment to quick and efficient product development, Novera is focused on orphan drug designations for both acute and chronic wound treatments and rely on out-licensing for much of the late-stage responsibilities such as marketing and distribution.
